The REMS Ramp Up: FDA Using New Safety Tools More Frequently In Year Two
Executive Summary
FDA is using its new Risk Evaluation and Mitigation Strategy authorities much more frequently in the second year since the law took effect
You may also be interested in...
REMS Reform Looks To Be Theme Of PDUFA V: Stakeholders Call For Standardization, Earlier Notice
The biggest changes that came out of the FDA Amendments Act, the last round of Prescription Drug User Fee Act reauthorization, were FDA's augmented drug safety authorities, most specifically the Risk Evaluation and Mitigation Strategy tool. Going into the next round of PDUFA negotiations, a major focus will be on improving the implementation of the REMS program
REMS Reform Looks To Be Theme Of PDUFA V: Stakeholders Call For Standardization, Earlier Notice
The biggest changes that came out of the FDA Amendments Act, the last round of Prescription Drug User Fee Act reauthorization, were FDA's augmented drug safety authorities, most specifically the Risk Evaluation and Mitigation Strategy tool. Going into the next round of PDUFA negotiations, a major focus will be on improving the implementation of the REMS program
FDA To Ask Advisory Committees To Review Phase IV Safety Trial Designs
FDA is preparing to take proposals for large post marketing studies to its drug advisory committees to solicit outside advice and counsel on the design and term of the new mandatory studies